Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial
Jean‐Pierre Gérard(Centre Antoine Lacassagne), Béata Juzyna(UniCancer Group), Valérie Boige(Inserm), Guy de Laroche(Centre Hospitalier Universitaire de Saint-Étienne), Marc-André Mahé(American Society of Clinical Oncology), S. Gourgou-Bourgade(CEA Valduc), K. Bénézéry(Centre Antoine Lacassagne), Emmanuel Chamorey(Centre Antoine Lacassagne)
Cited by 82
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k